FDA's Thinking On New Psychiatric Endpoints: What Does Brintellix CRL Portend For Nuplazid?
Executive Summary
FDA deviated from its advisory committee's recommendation on the first cognitive function claim for an antidepressant when it issued a complete response letter for Brintellix. The decision could signal trouble for Acadia's Nuplazid for Parkinson's psychosis, which also relies on a new psychiatric endpoint.
You may also be interested in...
Will Alkermes Data Package Support ALKS 5461 Approval?
Alkermes revealed successful completion of its third Phase III trial for the depression drug ALKS 5461 as well as a risky plan to seek FDA approval based on two negative and one positive late-stage study.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.